Ashdin Publishing
Journal of Evolutionary Medicine
Vol:12 (2024) Article ID 150309, 01 page
doi:10.4303/jem/150309

Commentary

Comparative Studies of Adaptive Immunity: Evolutionary Insights into Vaccination and Immune System Development

Shazib Pervaiz*

Department of Neuroscience, Johns Hopkins University, USA

**Address Correspondence to Shazib Pervaiz, Email: parvazibshaiz@gmail.com*

Received: 01 October 2024; Manuscript No: JEM-24-150309; **Editor assigned:** 03 October 2024; PreQC No: JEM-24-150309 (PQ); **Reviewed:** 17 October 2024; QC No: JEM-24-150309; **Revised:** 22 October 2024; Manuscript No: JEM-24-150309 (R); **Published:** 29 October 2024; **DOI:** 10.4303/JEM/150309

Description

The adaptive immune system is one of the cornerstones of vertebrate immunity, providing tailored protection against a vast array of pathogens. Unlike the innate immune system, which offers broad, non-specific defense mechanisms, adaptive immunity is characterized by its ability to recognize and respond to specific pathogens with remarkable precision. This specificity and memory allow adaptive immunity to be the basis of effective vaccination strategies and the evolution of immune system development across species. Comparative studies of adaptive immunity, by examining how various organisms have evolved these complex systems, offer profound insights into immune function and potential applications for improving human health. Both cell types are part of the lymphatic system and are involved in creating immunological memory, enabling the immune system to recognize previous invaders and respond more rapidly upon re-exposure. Unlike the innate immune system, which is present from birth, the adaptive immune system requires previous exposure to a pathogen or a vaccination to develop an effective response. To understand the complexity and evolution of adaptive immunity, researchers have studied a wide range of species, from primitive jawless vertebrates to modern mammals. By comparing the immune systems of different organisms, we can trace the evolutionary origins of adaptive immunity and explore how it has adapted to diverse ecological niches. The earliest evidence of adaptive immunity comes from jawless fish, such as lampreys and hagfish, which possess a unique form of immunity that does not rely on T and B cells. These fish use a family of proteins known as variable lymphocyte receptors (VLRs), which function in a similar manner to antibodies but are evolutionarily distinct. Despite this difference, VLRs allow lampreys to recognize a broad array of pathogens, much like how antibodies function in higher vertebrates. This suggests that adaptive immune systems likely evolved in jawless fish before the advent of T and B cells in jawed vertebrates. The evolution of T and B cells is considered a critical step in the development of adaptive immunity. In contrast to the primitive VLRs, T and B cells use a highly diversified set of receptors generated through recombination, allowing for a broader, more efficient immune response. This feature is essential for vaccine efficacy in higher vertebrates, including humans, as it allows for the generation of high-affinity antibodies that provide long-lasting immunity. For instance, in many reptiles, the immune memory is not as long-lasting, and responses to secondary infections can be less efficient, reflecting the evolutionary trade-offs in immune system development across species. The ability of these cells to persist and rapidly respond to pathogens after an initial exposure allows vaccines to confer long-term immunity with minimal risk. The evolutionary insights gained from comparative studies of adaptive immunity have profound implications for the development of vaccines. By harnessing the natural capacity of the immune system to produce antibodies in response to a pathogen, scientists have been able to improve vaccine efficacy and safety. In some species, adjuvants naturally exist as part of their immune responses, while in others, such as mammals, adjuvants are introduced artificially to boost the effectiveness of vaccines.

Acknowledgement

None.

Conflict of Interest

None.